Essential Preventive Measures: Schedule comprehensive baseline eye examinations before starting GLP-1 therapy to establish documented visual function parameters Maintain routine ophthalmological appointments at intervals recommended by healthcare providers, typically every six to twelve months Report any sudden changes in vision, including blurred vision, dark spots, or peripheral vision loss, immediately to medical professionals Document Everything: Document all visual symptoms with specific details regarding onset, duration, and severity for accurate medical assessment Optic Nerve Heath: Request specific screening for optic nerve health and evaluation of risk factors associated with NAION Pre-existing Conditions: If you have existing conditions such as diabetes, hypertension, or cardiovascular disease, youll need closer monitoring because these conditions increase the risk of optic nerve damage
The combination is safe, well-tolerated, and synergistic
b , cAMP accumulation studies using GLP-1 and TT-OAD2 as the agonist in wild-type HEK293 cells and HEK293 cells in which G s/olf (G s ) or all G i/o/z (G i/o/z ) have been depleted using CRISPRCas9
In August 2023, Marrero ended up in the hospital with abdominal pain, nausea, vomiting, difficulty swallowing and rectal bleeding